Study: Malignant Pheo, Paraganglioma, Metastatic Carcinoid
NOTE: This study is ongoing, but not recruiting participants. The information and link is still being provided for those interested in the content of this study.
is located in Cambridge, MA, USA.
The actual trial is being conducted at various locations indicated at the official link given below.
This is the ongoing trial of Ultratrace 131 I MIBG (Azedra) therapy for pheochromocytoma and paraganglioma. There was a previous trial in which enrollment is complete. Azedra is presently available through an ongoing Phase 2 clinical trial that is being conducted at 12 centers in the United States, ten of which are presently active and enrolling. Twenty patients with relapsed/refractory malignant pheochromocytoma have received treatment so far. We have been given information in an effort to provide the information needed to contact the clinical trial’s physician investigators to discuss the details of the Azedra therapy, and the requirements of trial to determine if this is the right treatment. Additional information can be found by going to the ClinicalTrials.gov website and searching for study registration number NCT00874614.
This study benefits patients with certain types of pheochromocytoma, paraganglioma or metastatic carcinoid tumors. The radiopharmaceutical Iobenguane I 131 has been in use to treat and image neuroendocrine tumors since the 1980’s. A highly pure version of iobenguane has been developed (Ultratrace Iobenguane I 131) and it is believed that this newer form will be an improvement over the existing Iobenguane I 131 in terms of safety and efficacy. The purpose of this study is to test the safety and distribution of Ultratrace Iobenguane I 131 in patients with malignant pheochromocytoma, paraganglioma or metastatic carcinoid tumors. This dosimetry study will measure how long it takes for the drug to be absorbed and passed through the body and how much radioactivity is absorbed into different tissues of the body.